CN Patent

CN110191720A — 用于治疗血液学癌症的抗-CD20抗体、PI 3激酶-δ抑制剂以及抗-PD-1或抗-PD-L1抗体的组合

Assigned to French Fractionation And Biotechnology Laboratory · Expires 2019-08-30 · 7y expired

What this patent protects

本发明公开提供通过向有需要的受试对象给予治疗有效量的以下物质来治疗或减慢血液学恶性肿瘤的进展的方法和试剂盒：(i)PI3激酶(PI3K)‑δ的至少一种抑制剂(例如TGR‑1202)；(ii)至少一种抗‑CD20抗体(例如ublituximab)；以及(iii)至少一种抗‑PD‑1抗体(例如派姆单抗)或者抗‑PD‑L1抗体(例如atezolizumab)。还提供了治疗方案。

USPTO Abstract

本发明公开提供通过向有需要的受试对象给予治疗有效量的以下物质来治疗或减慢血液学恶性肿瘤的进展的方法和试剂盒：(i)PI3激酶(PI3K)‑δ的至少一种抑制剂(例如TGR‑1202)；(ii)至少一种抗‑CD20抗体(例如ublituximab)；以及(iii)至少一种抗‑PD‑1抗体(例如派姆单抗)或者抗‑PD‑L1抗体(例如atezolizumab)。还提供了治疗方案。

Drugs covered by this patent

Patent Metadata

Patent number
CN110191720A
Jurisdiction
CN
Classification
—
Expires
2019-08-30
Drug substance claim
No
Drug product claim
No
Assignee
French Fractionation And Biotechnology Laboratory
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.